AbbVie Inc. (ABBV) fair value analysis
S&P 500 · Updated 2026-10-19
ABBV price how computed
Forward Fair Value verdict
OvervaluedABBV is trading at a 10–25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $276.47
- Sector
- Healthcare
- 12-month range
- $197.38–$285.42
- Market cap
- $489B
- From 52-week high
- -3.1%
- Shares outstanding
- 1.77B
- Rank in Healthcare by discount to fair value
- #78 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
AbbVie Inc. is a biopharmaceutical company that discovers, develops, manufactures, and markets a broad range of pharmaceutical products, including treatments for immunology, oncology, virology, and other therapeutic areas. The company operates globally with a significant presence in North America, Europe, and international markets.
ABBV currently ranks #78 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 6 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $489B
- P/E (trailing)
- 25x
- Revenue (TTM)
- $64.4B
- Net margin
- 9.8%
- EPS (TTM)
- $10.87
- Gross margin
- 74.7%
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- 7.3%
- Shares outstanding
- 1.77B
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Stable
- 52-week position
- The top quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 73 · overbought
- 50-day average
- $262.45
- 200-day average
- $233.95
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Dividends how computed
- Paid, last 12 months
- $6.92 per share (4 payments)
- Yield on last price
- 2.50%
- Consecutive years of increases
- 12
- Last ex-dividend date
- 2026-10-15
- Last payment date
- 2026-11-16
Earnings how computed
- Next earnings report
- 2026-10-30 (pre-market)
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+0.3%)
2026-03 ▼ miss (-0.7%)
2025-12 ▲ beat (+2.3%)
2025-09 ▲ beat (+4.5%)
2025-06 ▲ beat (+2.1%)
2025-03 ▲ beat (+2.5%)
2024-12 ▲ beat (+1.9%)
2024-09 ▲ beat (+2.7%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 24 buy · 5 hold · 1 sell (30 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $283
- Target vs last price
- +2.4%
What our data shows for ABBV
- Our model validated 17 trailing price-to-earnings windows for ABBV, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $197.38–$285.42.
- The 14-day relative strength index sits at an overbought 73.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for ABBV
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent ABBV news
TickrTrends' derived news-sentiment signal for ABBV is currently leaning positive, computed from recent coverage.
- AbbVie (ABBV) Reports Promising Phase 2a Data for ABBV-466 in Crohn's Disease (gurufocus.com, 2026-10-19)
TickrTrends take: AbbVie reported positive interim results for its investigational Crohn's disease treatment, which could strengthen its pipeline and potentially support future revenue growth. However, TickrTrends currently assesses ABBV as overvalued, suggesting that positive clinical developments may already be reflected in the stock price or that current valuations leave limited room for near-term upside. Investors relying on valuation metrics should monitor whether successful phase progression of ABBV-466 eventually justifies the company's current market assessment or whether valuation multiples remain disconnected from clinical progress. - AbbVie (ABBV) to Showcase Expanded Solid Tumor Research at ESMO Congress (gurufocus.com, 2026-10-19)
TickrTrends take: AbbVie's presentation of expanded solid tumor research at ESMO Congress represents potential pipeline progress in an area critical to justifying the company's current Healthcare sector valuation. Given TickrTrends' assessment that ABBV is overvalued, investors focused on valuation metrics should monitor whether these research developments translate into near-term revenue drivers or remain longer-term prospects. The market's response to this clinical data will be relevant context for evaluating whether the stock's current price adequately reflects the timing and commercial potential of these solid tumor programs. - AbbVie (ABBV) Showcases Long-Term IBD Data at UEG Week 2026 (gurufocus.com, 2026-10-18)
TickrTrends take: AbbVie presented long-term inflammatory bowel disease data at UEG Week 2026, which could influence investor assessments of the company's pipeline strength and competitive positioning in a key therapeutic area. Given TickrTrends' current overvalued verdict for ABBV, investors focused on valuation should monitor whether this clinical data translates into revenue growth sufficient to justify the stock's current market price relative to peers in the Healthcare sector. The durability and safety profile demonstrated in such long-term studies may become particularly relevant if the market reassesses ABBV's growth prospects and risk profile.
More ABBV news
- Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment? (insidermonkey.com, 2026-10-16)
- AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive? (insidermonkey.com, 2026-10-16)
- AbbVie (ABBV) Expands Board to 13 Directors with Appointment of Dr. John M. Carethers (gurufocus.com, 2026-10-16)
- AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know (zacks.com, 2026-10-14)
- AbbVie (ABBV) Highlights Promising IBD Data at ACG 2026 Amid Dividend Sustainability Focus (gurufocus.com, 2026-10-11)
- AbbVie (ABBV) Pays Out More Than It Earns. How Long Can That Hold? (insidermonkey.com, 2026-10-07)
- AbbVie (ABBV) Flags $216M Q3 Charge Impacting Earnings Amid Dividend Focus (gurufocus.com, 2026-10-05)
What people are saying
Follow the ABBV conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — ABBV moved into overbought territory this week as its RSI zone shifted from neutral to overbought, indicating increased upward momentum in the stock price. The current valuation assessment remains overvalued, suggesting the stock's price may have risen ahead of its fundamental value. These technical changes warrant monitoring to see whether the overbought condition leads to a pullback or continued strength.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for ABBV shifted this week, with the valuation verdict changing from Fairly valued to Overvalued. This change reflects a movement toward higher valuation multiples relative to the company's fundamentals. The healthcare sector stock is now trading at levels that exceed fair value according to TickrTrends' assessment.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ABBV stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), ABBV is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is ABBV's TickrTrends verdict?
ABBV's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does ABBV compare to other Healthcare stocks?
ABBV ranks #78 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is ABBV overbought or oversold?
ABBV's 14-day RSI is in the overbought zone on TickrTrends' latest weekly data.
Does ABBV pay a dividend?
Yes. ABBV paid $6.92 per share over the last twelve months (4 payments), a 2.50% yield on TickrTrends' last price, and has raised the annual total for 12 consecutive years. The last ex-dividend date was 2026-10-15.
When does ABBV report earnings next?
ABBV's next earnings report is scheduled for 2026-10-30 (pre-market), per the published earnings calendar.
Does ABBV usually beat earnings estimates?
Over its last 8 reported quarters ABBV beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ABBV?
Of 30 analysts covering ABBV, 24 rate it a buy, 5 a hold and 1 a sell - buy-leaning, with a consensus price target of $283 (+2.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
ABBV vs ACAD · ABBV vs AMGN · ABBV vs BIO · ABBV vs CAH · ABBV vs CNC